Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 7310694, 8 pages
http://dx.doi.org/10.1155/2016/7310694
Research Article

Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis

1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
2Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing 100069, China
3Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK

Received 20 April 2016; Accepted 8 June 2016

Academic Editor: Yichuan Zhao

Copyright © 2016 Chengcheng Hao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. DeSantis, S. A. Fedewa, A. G. Sauer, J. L. Kramer, R. A. Smith, and A. Jemal, “Breast cancer statistics, 2015: convergence of incidence rates between black and white women,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 31–42, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Fan, K. Strasser-Weippl, J.-J. Li et al., “Breast cancer in China,” The Lancet Oncology, vol. 15, no. 7, pp. e279–e289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. P. H. Anborgh, L. B. R. Caria, A. F. Chambers, A. B. Tuck, L. W. Stitt, and M. Brackstone, “Role of plasma osteopontin as a biomarker in locally advanced breast cancer,” American Journal of Translational Research, vol. 7, no. 4, pp. 723–732, 2015. View at Google Scholar · View at Scopus
  4. A. Martinetti, E. Bajetta, L. Ferrari et al., “Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 771–779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Singhal, D. S. Bautista, K. S. Tonkin et al., “Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival,” Clinical Cancer Research, vol. 3, no. 4, pp. 605–611, 1997. View at Google Scholar · View at Scopus
  6. A. B. Tuck, F. P. O'Malley, H. Singhal et al., “Osteopontin expression in a group of lymph node negative breast cancer patients,” International Journal of Cancer, vol. 79, no. 5, pp. 502–508, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. P. S. Rudland, A. Platt-Higgins, M. El-Tanani et al., “Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer,” Cancer Research, vol. 62, no. 12, pp. 3417–3427, 2002. View at Google Scholar · View at Scopus
  8. N. Liao, L. L. Tang, Z. Q. Wang, Z. G. Liao, and C. J. Zhang, “Expression of OPN in recurrent and metastatic breast cancer,” Modern Oncology, vol. 4, pp. 692–695, 2010. View at Google Scholar
  9. F. Ortiz-Martínez, A. Perez-Balaguer, D. Ciprián et al., “Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence,” Human Pathology, vol. 45, no. 3, pp. 504–512, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Pang, H. Lu, H. Song et al., “Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer,” Cancer Epidemiology, vol. 37, no. 6, pp. 985–992, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Zduniak, P. Ziolkowski, C. Ahlin et al., “Nuclear osteopontin-c is a prognostic breast cancer marker,” British Journal of Cancer, vol. 112, no. 4, pp. 729–738, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Patani, F. Jouhra, W. Jiang, and K. Mokbel, “Osteopontin expression profiles predict pathological and clinical outcome in breast cancer,” Anticancer Research, vol. 28, no. 6, pp. 4105–4110, 2008. View at Google Scholar · View at Scopus
  13. D. T. Denhardt and M. Noda, “Osteopontin expression and function: role in bone remodeling,” Journal of Cellular Biochemistry, vol. 30, pp. 92–102, 1998. View at Google Scholar
  14. C. M. Giachelli and S. Steitz, “Osteopontin: a versatile regulator of inflammation and biomineralization,” Matrix Biology, vol. 19, no. 7, pp. 615–622, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. K. X. Wang and D. T. Denhardt, “Osteopontin: role in immune regulation and stress responses,” Cytokine & Growth Factor Reviews, vol. 19, no. 5-6, pp. 333–345, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. R. Rittling and A. F. Chambers, “Role of osteopontin in tumour progression,” British Journal of Cancer, vol. 90, no. 10, pp. 1877–1881, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Coppola, M. Szabo, D. Boulware et al., “Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies,” Clinical Cancer Research, vol. 10, no. 1, pp. 184–190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Chakraborty, S. Jain, and G. C. Kundu, “Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms,” Cancer Research, vol. 68, no. 1, pp. 152–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. B. Tuck and A. F. Chambers, “The role of osteopontin in breast cancer: clinical and experimental studies,” Journal of Mammary Gland Biology and Neoplasia, vol. 6, no. 4, pp. 419–429, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. V. H. C. Bramwell, G. S. Doig, A. B. Tuck et al., “Serial plasma osteopontin levels have prognostic value in metastatic breast cancer,” Clinical Cancer Research, vol. 12, no. 11, pp. 3337–3343, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mänsson, “The role of osteopontin in tumor progression and metastasis in breast cancer,” Cancer Epidemiology Biomarkers & Prevention, vol. 16, no. 6, pp. 1087–1097, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. F. Young, J. M. Kerr, J. D. Termine et al., “cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN),” Genomics, vol. 7, no. 4, pp. 491–502, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Hijiya, M. Setoguchi, K. Matsuura, Y. Higuchi, S. Akizuki, and S. Yamamoto, “Cloning and characterization of the human osteopontin gene and its promoter,” Biochemical Journal, vol. 303, no. 1, pp. 255–262, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Rangaswami, A. Bulbule, and G. C. Kundu, “Osteopontin: role in cell signaling and cancer progression,” Trends in Cell Biology, vol. 16, no. 2, pp. 79–87, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Bautista, J.-W. Xuan, C. Hota, A. F. Chambers, and J. F. Harris, “Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin,” The Journal of Biological Chemistry, vol. 269, no. 37, pp. 23280–23285, 1994. View at Google Scholar · View at Scopus
  26. Y. Yokosaki, N. Matsuura, T. Sasaki et al., “The integrin α9β1 binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin,” The Journal of Biological Chemistry, vol. 274, no. 51, pp. 36328–36334, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. B. He, M. Mirza, and G. F. Weber, “An osteopontin splice variant induces anchorage independence in human breast cancer cells,” Oncogene, vol. 25, no. 15, pp. 2192–2202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Mirza, E. Shaughnessy, J. K. Hurley et al., “Osteopontin-c is a selective marker of breast cancer,” International Journal of Cancer, vol. 122, no. 4, pp. 889–897, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Sun, A. Feng, S. Chen et al., “Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1,” Cellular & Molecular Immunology, vol. 10, no. 2, pp. 176–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. P. S. Rudland, A. Platt-Higgins, M. El-Tanani et al., “Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer,” Cancer Research, vol. 62, no. 12, pp. 3417–3427, 2002. View at Google Scholar · View at Scopus
  31. Y. Y. Xu, Y. Y. Zhang, W. F. Lu, Y. J. Mi, and Y. Q. Chen, “Prognostic value of osteopontin expression in breast cancer: a meta-analysis,” Molecular and Clinical Oncology, vol. 3, pp. 357–362, 2015. View at Google Scholar
  32. Y. Liu, X. Gu, Q. Lin et al., “Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 8, pp. 12765–12773, 2015. View at Google Scholar · View at Scopus
  33. M. Zhao, F. Liang, B. Zhang, W. Yan, and J. Zhang, “The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis,” Scientific Reports, vol. 10, pp. 1038–1045, 2015. View at Google Scholar
  34. J.-J. Li, H.-Y. Li, and F. Gu, “Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis,” Genetic Testing and Molecular Biomarkers, vol. 18, no. 8, pp. 580–586, 2014. View at Publisher · View at Google Scholar · View at Scopus